Cervical Cancer Treatment Delays and Associated Factors in a Cohort of Women From a Developing Country

Ileia Ferreira da Silva, MSc1,2; Ilce Ferreira da Silva, PhD1,3; and Rosalina Jorge Koifman, PhD1

abstract

PURPOSE To estimate treatment delays and associated factors among women diagnosed with cervical cancer who were treated at the main cancer center in Rio de Janeiro, Brazil.

MATERIALS AND METHODS A retrospective cohort study was performed comprising 865 women newly diagnosed with cervical cancer between 2012 and 2014. Times from diagnosis to treatment initiation (less than or equal to 60 days) and from diagnosis to treatment ending (less than or equal to 120 days) were analyzed according to the Brazilian law for the treatment of patients with cancer. Associations between treatment delays and sociodemographic, economic, lifestyle, clinical, and treatment variables were estimated using logistic regression models, with 95% CIs.

RESULTS The average age was 48 (± 13.7) years, and the median age was 47 years; 36.2% of patients had stage IIIB to IVA disease. The median time from diagnosis to treatment initiation was 114 days, which was statistically higher among women with stage IIB to IVA (105.5 days) compared with those with earlier stages (119 days). The delay in treatment initiation occurred in 92.8% of participants; the median time from diagnosis to treatment ending was 274 days, with a delay (more than 120 days) for 92.6% of patients. The median time interval from diagnosis to the first visit to the cancer center was 28 days, with a delay of more than 30 days for 46.6% of patients. Age (odds ratio [OR], 1.05; 95% CI, 1.02 to 1.08), stage IIIB to IVA (OR, 0.38; 95% CI, 0.16 to 0.90), time to first visit to the cancer center (OR, 11.52; 95% CI, 4.32 to 30.66), chemoradiation treatment (OR, 4.56; 95% CI, 1.81 to 11.47), and adequate treatment (OR, 2.57; 95% CI, 1.26 to 5.40) were independently associated with delay of treatment initiation.

CONCLUSION Significant delays in treatment initiation and ending were observed in this studied population. The treatment initiation delay was positively associated with age, time interval more than 30 days from diagnosis to first specialist assessment at the cancer center, treatment with chemoradiation, and adequate treatment.

INTRODUCTION

Cervical cancer is an important public health problem worldwide, especially in developing countries, where it is the second most common cancer among women.1 Developed countries with broad-coverage Papanicolaou-test screening programs have experienced a decline in cervical cancer incidence and mortality over the past decades.2 However, in developing countries, cervical cancer incidence and mortality rates are still considered high, and survival is poor.1,3,8 Such rates could be attributed to late organization of screening programs, low access to the health care system, low education level of the population at risk, and delays in diagnosis and treatment of this neoplasia.2,5,8,12

Cervical cancer treatment is usually either chemoradiation or radical hysterectomy/trachelectomy with lymph node dissection in early stages and chemoradiation in advanced stages. Depending on the patient’s health status, such as age, comorbidity, and disease presentation, the treatment may be adjusted accordingly.13 Delays in diagnosis and treatment initiation and/or conclusion are experienced by patients with cervical cancer regardless of the country and/or institution they are being treated.9,14,15 Long waiting times for surgery or radiation are usually associated with poor access to services, poor quality of health care,14-18 and request for a second opinion or time-consuming pathologist reviews that might affect treatment.16 Delays can also be due to patient factors, such as sociodemographic factors, comorbidities, social influences, and previous experiences.19,20

According to international standards for early cancer diagnosis and treatment, the time intervals that should
be measured include appraisal (interval from bodily changes and patient appraisal and self-management); help-seeking (time to decide to consult a hospital cancer physician/practitioner and arrange an appointment); diagnostic (interval between first consultation with a health care practitioner and diagnosis); and pretreatment (time interval from diagnosis to start of treatment).20-22 Regarding cervical cancer, time intervals from diagnosis to treatment initiation and completion are also important to guarantee treatment efficacy and improve survival.9,12,14,23 Evidence supports that a waiting time of more than 60 days from cancer diagnosis to treatment initiation could lead to poorer survival compared with women who start treatment within 60 days after diagnosis.24 The National Breast and Cervical Cancer Early Detection and Treatment Program indicator of timely follow-up (National Comprehensive Cancer Network) postulated that severe therapeutic care delay was defined as a delay of 60 days or more from final cervical cancer diagnosis to the initiation of treatment.25 Also, a delay of cancer therapeutic care greater than 3 months could harm prognosis, increase morbidity, reduce survival, and jeopardize survivorship.26,27 However, some studies did not find statistical significance on delays to treatment and survival rates among women with cervical cancer in the United States.12,23 Such controversy could be due to delay-to-treatment definitions, study population base (hospital based v population based), sample size, stage at diagnosis, treatment protocols, and time interval from treatment initiation to conclusion.25,28

Brazilian public health care is universal and covers approximately 70% of cervical cancer treatment in the country.29 The Brazilian government issued a law in 2012 determining that every patient with cancer should start the treatment within 60 days from the date that diagnosis is histologically confirmed, aiming to guarantee the same treatment access to every user of the public health system.30 In 2013, another law was issued establishing that the counting of the time to treatment initiation should begin with the date that the diagnosis was registered on the medical report.31 To our knowledge, there is no study in Brazil evaluating the delays in cervical cancer treatment on the basis of international criteria. This study aimed to estimate treatment delays and associated factors among patients with cervical cancer referred to the Gynecologic Cancer Hospital of National Cancer Institute in Brazil (HC-II/NCI).

MATERIALS AND METHODS

Study Design and Participants

A retrospective study was performed in a cohort of women diagnosed with cervical cancer and referred to the HC-II/NCI in Rio de Janeiro. In 2010, the cancer care access regulation system was established in the city of Rio de Janeiro, creating a list of patients diagnosed with cancer and referring them to a cancer treatment center.32 Although the cancer treatment centers could still receive patients with cancer on the basis of free demand and/or who were referred by a private doctor or health care professional familiar with the institutional flow,32 a few women in the sample (n = 46) did not follow the regular flow of the public health care service.

All women newly diagnosed with cervical cancer (International Classification of Diseases code 10:C.53) from July, 1, 2012, to October, 31, 2014, were eligible. The inclusion criteria were all consecutive patients with a histologically confirmed diagnosis of cervical cancer (encompassing adenocarcinoma, squamous carcinoma, and adenosquamous carcinoma) who were completely treated at HC-II/NCI. Patients were identified and selected using the Hospital Cancer Registry (HCR/HC-II) database, and the registered diagnosis was cross-tabled with histopathologic reports. From 2012 to 2014, 1,483 women registered as C.53 (International Classification of Diseases code 10) in the HCR/HC-II database. Of these, 489 patients (33%) were excluded: 23 were treated at another cancer center, nine had a histologic result other than epithelial, 40 had a second primary cancer site, 140 received only brachytherapy at HC-II/NCI, and 201 had precancerous lesions on the histologic report; patients classified as stage IVB (n = 76) were excluded from the analysis because treatment at this stage is for symptomatic relief rather than curative purposes. Of 994 eligible patients, 204 (20.5%) were lost to follow-up: 45 because medical files were not found, and 159 had no treatment information. Thus, the studied population included 790 patients with cervical cancer (Fig 1). This study was approved by the Research Ethics Board at the National School of Public Health in Brazil.

Variables

Two trained nurses extracted all studied data from electronic and physical medical reports. Outcomes were set as three waiting times (Fig 2): T1—days from diagnosis to first specialist assessment (FSA; including the referral to the cancer center, scheduling the FSA, personal appraisal of the FSA); T2—days from diagnosis to first treatment initiation (including T1+ staging, treatment definition, preradiotherapy referral, presurgical tests, surgery appraisal); T3—days from diagnosis to treatment completion (including T1+T2+ dates and types of surgery, chemoradiation and radiation only, dates of treatment completion). Delays-in-treatment definitions were based on the literature and on sample distributions as follows: 30 days or less versus 30 days or more (T1); 60 days or less versus 60 days or more (T2)24,32; to 120 days or less versus 120 days or more (T3).24,25,32

Independent variables included sociodemographic characteristics, such as age at diagnosis, place of residence (Rio de Janeiro v other city/state), ethnicity (white/non-white), education (no education v high school/college),
Disease presentation and treatment were classified according to the International Federation of Gynecology and Obstetrics stage at diagnosis (I, II, III, and IV) and then were grouped as local early stages/bulky (IA1 to IIA2), locally advanced (IIB to IIIA), and late stage (IIIB to IV A). Additional classifications included histopathologic results (squamous carcinoma vs. adenocarcinoma/adenosquamous carcinoma), surgery (yes/no), external beam radiotherapy to the pelvis (yes/no), brachytherapy insertion (yes/no), and treatment protocol (surgery only/surgery plus chemoradiation/radiation only). Following International Federation of Gynecology and Obstetrics recommendations, treatment at stages IA2, IB, and IIA was either radical hysterectomy/radical trachelectomy with bilateral lymph node dissection or, alternatively, concurrent chemoradiation with a platinum-based regimen for radiosensitization. The latter treatment combination was administered to patients at stages IB2, IIB, III, and IVA. Adjuvant radiation was prescribed for patients who underwent radical hysterectomy/trachelectomy but were found postoperatively to have lymph node metastases, close or involved surgical margins, or parametrial involvement, or had at least two of the following risk factors: deep stromal invasion, lymphovascular space invasion, or tumor diameter greater than 4 cm. Thus, adequacy of treatment (yes/no) was established by combining the treatment protocol performed with the stage group.

### Statistical Analysis

Descriptive analyses were performed through frequency distributions of categorical variables according to stage. Percentage differences were evaluated through $\chi^2$ and Fisher tests, considering a significance level of 5%. Time intervals from histologic diagnosis and FSA to treatment initiation and to treatment completion were analyzed as

---

### FIG 1. Eligibility flow of studied population. HCR/HC-II, Hospital Cancer Registry/Gynecologic Cancer Hospital.

### FIG 2. Cervical cancer care pathway and outcome definitions. T1, days from diagnosis to First Specialist Assessment at HC-II/NCI. T2, days from diagnosis to first treatment initiation. T3, days from diagnosis to treatment conclusion.
continuous and categorical variables. Median differences among time intervals, according to stage and treatment, were analyzed using the Kruskal-Wallis test and the Mann-Whitney U test, with a significance level of 5%.

Prevalence of initial treatment delays (greater than 60 days) for each covariable was categorized according to stage. Crude and stratified-by-stage odds ratios (ORs), with their respective 95% CIs, for treatment initiation delays were estimated using a nonconditional logistic regression model. Multiple logistic regressions were used to estimate adjusted ORs and 95% CIs using the Wald statistic test. Biologic relevance and statistical significance in crude analyses were the criteria to include the variables in the final model. A significance level of 5% was used to retain the variable in the model. Final model diagnosis was performed by means of a residual analysis, and the Hosmer-Lemeshow goodness-of-fit test. All analyses were performed using the SPSS statistical package (version 20.0; SPSS, Chicago, IL).

RESULTS

In this sample, 67.7% of patients presented for diagnosis at a late stage (a stage greater than IIB). 70.1% were older than 40 years of age, only 17.2% lived in Rio de Janeiro city, 67.5% were nonwhite, 71.8% had a low education level (less than elementary school), 63.4% had a family income of up to twice the minimum wage, and 74.3% received chemoradiation. Compared with women treated with surgery, those treated with chemoradiation were mainly older than 40 years of age (74.1%), had lower education levels (75.8%), and had a higher frequency of stage IIB or greater at diagnosis (85.8%). However, they also had a lower frequency of adenocarcinoma (13.6%), adequate treatment (58.1%), and less FSA delay (43.9%; Table 1).

The median time interval from diagnosis to FSA was 28 days, varying from 27 days among the radiotherapy group to 37 days among the surgery group and from 26.5 days in the stage IIB to IVA group to 33 days in the stage IA1 to IIA2 group (Table 2). The median time from diagnosis to treatment initiation was 114 days, varying from 105 days among patients with stage IIB to IVA disease to 119 days among patients with earlier stages. Only 7.2% of this population initiated treatment before 60 days, and 68.8% initiated it in more than 90 days. Only 4% of the women with stage IIB disease were treated within 60 days, whereas approximately 8.5% of those with earlier and later stages were treated within this period (Table 2). The median time from diagnosis to treatment conclusion was 274.5 days, varying from 268 days for women treated with radiation to 357 days among those treated with surgery (P < .001). Considering the stage at diagnosis, the median time varied from 252 days among women at stage IIB to IVA to 302 days among women at stage IIA1 to IIAB (P < .001). Only 7.4% completed treatment within 120 days, varying from 5.3% among the women treated with surgery to 7.6% among those treated with radiation. Overall, 75% completed the treatment in more than 200 days, whereas among those treated with surgery, 90.3% had a time interval of more than 200 days from diagnosis to treatment conclusion (P = .003). On the basis of the stage at diagnosis, only 0.9% of women with early-stage disease concluded treatment within 120 days, whereas 11.4% of patients with stage IIIB to IVA and 5.8% of patients with stage IIB to IIAB concluded in this period (P = .001). Also, 68.3% of later-stage patients (IIIB to IVA) and more than 80% of patients in earlier stages concluded treatment in more than 200 days (Table 2).

The prevalence of treatment initiation delays was more than 80% for all variables evaluated (Table 3). Overall, age older than 40 years (OR, 2.18; 95% CI, 1.26 to 3.77); nonwhite ethnicity (OR, 2.04; 95% CI, 1.18 to 3.52); receipt of external radiation (OR, 1.83; 95% CI, 1.00 to 3.34); or brachytherapy (OR, 3.15; 95% CI, 1.80 to 5.53); being included in the chemoradiation protocol (OR, 1.84; 95% CI, 1.04 to 3.24); and time from diagnosis to FSA (OR, 8.53; 95% CI, 3.34 to 21.76) were positively associated with treatment initiation delay. Occupation level ≥ high school (OR, 0.43; 95% CI, 0.24 to 0.75), family income more than twice the minimum wage (OR, 0.52; 95% CI, 0.28 to 1.00), and receiving surgery as the first treatment (OR, 0.55; 95% CI, 0.31 to 0.96) were negatively associated with treatment initiation delays. Women with stage IA1 to IIA2 disease, living in a city other than Rio de Janeiro (OR, 3.08; 95% CI, 1.24 to 7.70), who were nonwhite (OR, 3.45; 95% CI, 1.34 to 8.60), and with more than 30 days from diagnosis to FSA (OR, 11.45; 95% CI, 2.60 to 50.54) were positively associated with delays. Women with later stages of disease (IIIB to IVA), older than 40 years of age (OR, 2.92; 95% CI, 1.24 to 6.85), receiving brachytherapy (OR, 4.14; 95% CI, 1.74 to 10.00), receiving adequate treatment (OR, 4.00; 95% CI, 1.56 to 9.74), and with more than 30 days to FSA (OR, 5.00; 95% CI, 1.43 to 17.40) were statistically associated with treatment initiation delays.

In the multiple logistic regression (Table 4), delays were independently associated with age (OR, 1.05; 95% CI, 1.02 to 1.08), having later stage at diagnosis (OR, 0.38; 95% CI, 0.16 to 0.90), spending over 30 days from diagnosis to FSA (OR, 11.52; 95% CI, 4.32 to 30.66), receiving chemoradiation treatment (OR, 4.56; 95% CI, 1.81 to 11.47), and receiving adequate treatment protocol (OR, 2.57; 95% CI, 1.26 to 5.40).

DISCUSSION

To our knowledge, this study is the first one in Brazil to describe the clinical pathway for women with cervical cancer at stages IA1 to IVA. The overall median time from histopathologic diagnosis to first treatment initiation was 114 days, despite the type of treatment indicated, being slightly shorter among late-stage patients (105 days). This reality is potentially concerning, because less than 10% of the study population was treated within 60 days from
### TABLE 1. Characteristic Distributions of a Cohort of Women Diagnosed With Cervical Cancer and Treated at National Cancer Institute, Rio de Janeiro, Brazil (2012 to 2014)

| Characteristic                  | Total Patients | Surgery Only | Surgery Plus Radiation | Chemoradiation | $\chi^2$ Test $P$ |
|--------------------------------|----------------|--------------|------------------------|----------------|-----------------|
| Patients, No.                  | 790 (100)      | 147 (18.6)   | 56 (0.1)               | 587 (74.3)     | < .001          |
| Age at diagnosis, years        |                |              |                        |                |                 |
| < 40                           | 236 (29.9)     | 66 (44.9)    | 24 (42.9)              | 146 (24.9)     | < .001          |
| ≥ 40                           | 554 (70.1)     | 81 (55.1)    | 32 (57.1)              | 441 (74.1)     |                 |
| Residency                      |                |              |                        |                | .80             |
| Rio de Janeiro                 | 136 (17.2)     | 34 (23.1)    | 11 (19.6)              | 91 (15.5)      |                 |
| Other cities/states            | 654 (82.8)     | 113 (76.9)   | 45 (80.4)              | 496 (84.5)     |                 |
| Ethnicity                      |                |              |                        |                | .138            |
| White                          | 257 (32.5)     | 59 (39.5)    | 17 (30.4)              | 182 (31.0)     |                 |
| Nonwhite                       | 533 (67.5)     | 89 (60.5)    | 39 (69.6)              | 405 (69.0)     |                 |
| Education                      |                |              |                        |                | < .001          |
| ≤ Middle school                | 567 (71.8)     | 85 (57.8)    | 37 (66.1)              | 445 (75.8)     |                 |
| > Middle school                | 223 (28.2)     | 62 (42.0)    | 19 (33.9)              | 142 (24.2)     |                 |
| Occupation level               |                |              |                        |                | < .001          |
| < High school                  | 558 (72.6)     | 83 (58.0)    | 36 (65.5)              | 439 (76.9)     |                 |
| ≥ High school                  | 211 (27.4)     | 60 (42.0)    | 19 (34.5)              | 132 (23.1)     |                 |
| Family income†                 |                |              |                        |                | .041            |
| ≤ Twice the minimum wage       | 408 (63.4)     | 67 (54.0)    | 34 (70.8)              | 307 (65.0)     |                 |
| > Twice the minimum wage       | 236 (36.6)     | 57 (46.0)    | 14 (29.2)              | 165 (35.0)     |                 |
| Comorbidity                    |                |              |                        |                | .241            |
| No                             | 125 (16.8)     | 18 (12.9)    | 06 (12.5)              | 101 (18.2)     |                 |
| Yes                            | 618 (83.2)     | 121 (87.1)   | 42 (87.5)              | 455 (81.8)     |                 |
| Smoking                        |                |              |                        |                | .266            |
| Never                          | 439 (55.8)     | 92 (62.6)    | 34 (60.7)              | 313 (53.6)     |                 |
| Former                         | 183 (23.3)     | 26 (17.7)    | 11 (19.6)              | 146 (25.0)     |                 |
| Current                        | 165 (21.0)     | 29 (19.7)    | 11 (19.6)              | 125 (21.4)     |                 |
| Histology                      |                |              |                        |                | < .001          |
| Squamous cell carcinoma        | 638 (82.7)     | 102 (71.3)   | 40 (74.1)              | 496 (86.4)     |                 |
| Adenocarcinoma                 | 133 (17.3)     | 41 (28.7)    | 14 (25.9)              | 78 (13.6)      |                 |
| Stage                          |                |              |                        |                | < .001          |
| IA1-IIA2                       | 255 (32.3)     | 141 (95.9)   | 31 (55.4)              | 83 (14.1)      |                 |
| IIB-III A                      | 249 (31.5)     | 03 (2.0)     | 11 (19.6)              | 235 (40.0)     |                 |
| IIIB-IVA                       | 286 (36.2)     | 03 (2.0)     | 14 (25.0)              | 269 (45.8)     |                 |
| Treatment adequacy             |                |              |                        |                | < .001          |
| Inadequate                     | 257 (32.5)     | 06 (4.1)     | 05 (8.9)               | 246 (41.9)     |                 |
| Adequate                       | 533 (67.5)     | 141 (95.9)   | 51 (91.1)              | 341 (58.1)     |                 |
| Time to FSA                    |                |              |                        |                | .027            |
| ≤ 30 days                      | 408 (53.4)     | 63 (43.8)    | 28 (50.9)              | 317 (56.1)     |                 |
| > 30 days                      | 356 (46.6)     | 81 (56.3)    | 27 (49.1)              | 248 (43.9)     |                 |

NOTE. Data are No. (%) unless otherwise indicated.
Abbreviation: FSA, first specialist assessment.
*TTotal may vary because of missing values.
†According to the minimum wage in the year of diagnosis.
diagnosis, although it was mandatory by law. In addition, a major variation in the time to complete the pathway was observed among the stages, with the median time reaching more than 300 days among women treated with surgery and among those in early stages (IA1 to IIA2).

The FSA timing varied from 27 days among women first treated with radiation to 37 days among women first treated with surgery. Thus, an FSA more than 30 days was the strongest factor independently associated with increased risk of treatment initiation delay. Similar findings were observed in New Zealand among women from the private and public sectors, where the median time from referral to treatment initiation for all patients was 97 days. A shorter median time to FSA in the private sector was associated with a reduction in median duration of the overall pathway and was the only factor significantly associated with reduced times from referral to treatment initiation in the multivariable analysis. Because our study was performed in the public sector only, our findings may reflect the patterns of health care use and the effectiveness of primary and secondary care services in Rio de Janeiro. Also, they may be a result of structural (geographic distance to the treatment facility and availability of transportation) and nonstructural (individual patient and physician factors) barriers. Although there is no specific recommendation regarding the acceptable waiting time from referral to FSA in Brazil, the United Kingdom National Health Service guidelines recommend that patients with either symptomatic or smear evidence of disease should have an FSA within 14 to 21 days. Should this recommendation be followed in Brazil, there would still be from 39 to 46 days left to proceed to staging, decision to treat, presurgery test/preradiotherapy referral, and surgery appraisal, meeting the Brazilian law requirement of 60 days from diagnosis to treatment initiation.

Studies have been published linking delays between diagnosis and the start of radiotherapy with adverse effects on cervical cancer treatment outcome. Since 1993,
### TABLE 3: Prevalence of Delays in Treatment Initiation and Associated Factors in a Cohort of Women Diagnosed With Cervical Cancer and Treated at National Cancer Institute, Rio de Janeiro, According to Stage at Diagnosis (2012 to 2014)

| Characteristics       | All Stages | IA1-IIA | IIB-IIIA | IIIB-IVA |
|-----------------------|------------|---------|----------|----------|
|                       | Prevalence | OR (95% CI) | Prevalence | OR (95% CI) | Prevalence | OR (95% CI) | Prevalence | OR (95% CI) |
| **Age, years**        |            |          |          |          |            |          |            |          |
| ≤ 40                  | 88.8       | 1        | 89.1     | 1        | 94.3       | 1        | 84.1       | 1        |
| > 40                  | 94.5       | 2.18 (1.26 to 3.77) | 92.9     | 1.60 (0.66 to 3.86) | 96.4       | 1.60 (0.40 to 6.42) | 93.9       | 2.92 (1.24 to 6.85) |
| **Residence**         |            |          |          |          |            |          |            |          |
| Rio de Janeiro        | 91.5       | 1        | 82.4     | 1        | 100        | 1        | 94.3       | 1        |
| Other cities/state    | 93.1       | 1.25 (0.625 to 2.48) | 93.5     | 3.08 (1.24 to 7.70) | 95.1       | —        | 91.1       | 6.20 (0.14 to 27.6) |
| **Ethnicity**         |            |          |          |          |            |          |            |          |
| White                 | 89.4       | 1        | 84.6     | 1        | 94.0       | 1        | 89.9       | 1        |
| Nonwhite              | 94.5       | 2.04 (1.18 to 3.52) | 95.0     | 3.45 (1.34 to 8.60) | 96.9       | 2.00 (0.56 to 7.11) | 92.1       | 1.32 (0.54 to 3.21) |
| **Education**         |            |          |          |          |            |          |            |          |
| ≤ Middle school       | 94.6       | 1        | 96.0     | 1        | 96.9       | 1        | 91.8       | 1        |
| > Middle school       | 88.2       | 0.42 (0.42 to 7.32) | 84.3     | 0.23 (0.85 to 0.60) | 92.7       | 0.41 (0.11 to 1.51) | 90.5       | 0.85 (0.23 to 2.24) |
| **Occupation level**  |            |          |          |          |            |          |            |          |
| < High school         | 94.7       | 1        | 94.0     | 1        | 96.9       | 1        | 93.3       | 1        |
| ≥ High school         | 88.5       | 0.43 (0.24 to 0.75) | 86.2     | 0.40 (0.16 to 0.97) | 91.8       | 0.36 (0.09 to 1.34) | 89.2       | 0.60 (0.23 to 1.54) |
| **Family income**     |            |          |          |          |            |          |            |          |
| ≤ Twice the minimum wage | 95.0  | 1         | 93.8     | 1        | 99.2       | 1        | 92.6       | 1        |
| > Twice the minimum wage | 91.0  | 0.53 (0.28 to 1.00) | 89.9     | 0.60 (0.22 to 1.60) | 92.4       | 0.10 (0.01 to 0.83) | 90.9       | 0.80 (0.28 to 2.25) |
| **Comorbidity**       |            |          |          |          |            |          |            |          |
| No                    | 92.7       | 1        | 85.7     | 1        | 96.9       | 1        | 94.7       | 1        |
| Yes                   | 92.8       | 1.00 (0.48 to 2.12) | 92.1     | 1.94 (0.66 to 5.70) | 95.6       | 0.70 (0.08 to 5.70) | 90.8       | 0.55 (0.16 to 1.92) |
| **Tobacco smoking**   |            |          |          |          |            |          |            |          |
| Never/former          | 92.7       | 1        | 91.1     | 1        | 96.8       | 1        | 90.6       | 1        |
| Current               | 93.8       | 1.20 (0.60 to 2.42) | 91.7     | 1.07 (0.35 to 3.32) | 93.0       | 0.43 (0.12 to 1.60) | 96.4       | 2.81 (0.64 to 12.34) |
| **Surgery**           |            |          |          |          |            |          |            |          |
| No                    | 94.0       | 1        | 95.2     | 1        | 95.7       | 1        | 92.0       | 1        |
| Yes                   | 89.4       | 0.55 (0.31 to 0.96) | 89.3     | 0.42 (0.40 to 1.30) | 100        | —        | 82.4       | 0.40 (0.11 to 1.52) |
| **External radiation**|            |          |          |          |            |          |            |          |
| No                    | 89.1       | 1        | 89.2     | 1        | 90.0       | 1        | 85.7       | 1        |
| Yes                   | 93.8       | 1.83 (1.00 to 3.34) | 93.8     | 1.82 (0.71 to 4.62) | 96.2       | 2.81 (0.32 to 24.67) | 91.3       | 1.83 (0.21 to 15.83) |

(Continued on following page)
| Characteristics | All Stages | IA1-IIA | IIB-IIA | IIIB-IVA |
|-----------------|-----------|---------|---------|----------|
|                 | Prevalence | OR (95% CI) | Prevalence | OR (95% CI) | Prevalence | OR (95% CI) | Prevalence | OR (95% CI) |
| Brachytherapy    | No        | 87.7 | 1 | 89.3 | 1 | 91.9 | 1 | 83.1 | 1 |
|                 | Yes       | 95.7 | 3.15 (1.80 to 5.53) | 94.6 | 2.08 (0.74 to 5.85) | 96.7 | 2.55 (6.30 to 10.33) | 95.3 | 4.14 (1.74 to 10.00) |
| Treatment protocol | Surgery* | 89.4 | 1 | 89.3 | 1 | 100 | 1 | 82.4 | 1 |
|                 | Chemoradiation | 94.0 | 1.84 (1.04 to 3.24) | 95.2 | 2.37 (0.77 to 7.24) | 95.7 | — | 92.1 | 2.5 (0.66 to 9.36) |
| Treatment protocol | Surgery only | 89.5 | 1 | 89.1 | 1 | 100 | 1 | 100 | 1 |
|                 | Surgery plus radiation | 89.3 | 0.97 (0.36 to 2.66) | 90.3 | 1.15 (0.31 to 4.23) | 100 | — | 78.6 | — |
| Chemoradiation  | 94.0 | 1.83 (0.97 to 3.45) | 95.2 | 2.43 (0.78 to 7.58) | 95.7 | — | 92.1 | — |
| Treatment adequacy | Inadequate | 90.4 | 1 | 95.2 | 1 | 94.2 | 1 | 85.3 | 1 |
|                 | Adequate | 94.0 | 1.64 (0.94 to 2.85) | 89.3 | 0.42 (0.14 to 1.30) | 96.4 | 1.64 (0.41 to 6.60) | 95.8 | 4.00 (1.56 to 9.74) |
| Time to FSA     | ≤ 30 days | 89.1 | 1 | 84.6 | 1 | 93.8 | 1 | 88.5 | 1 |
|                 | > 30 days | 98.6 | 8.53 (3.34 to 21.76) | 98.4 | 11.45 (2.60 to 50.54) | 100 | — | 97.5 | 5.00 (1.43 to 17.40) |

NOTE. Bold type indicates statistical significance.
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; FSA, first specialist assessment; OR, odds ratio.
*Surgery only or combined with radiation and/or chemotherapy.
Delays in Cervical Cancer Treatment in a Brazilian Cohort

TABLE 4. Crude and Adjusted ORs for Delay on Treatment Initiation (> 60 days) in a Cohort of Women Diagnosed With Cervical Cancer, Rio de Janeiro, Brazil (2012 to 2014)

| Characteristic       | Crude OR (95% CI) | Adjusted OR (95% CI)* |
|----------------------|-------------------|-----------------------|
| Age, years           | 1.04 (1.02 to 1.07) | 1.05 (1.02 to 1.08)   |
| Stage                |                   |                       |
| IA-IIA               | 1.04 (1.02 to 1.07) | 1.05 (1.02 to 1.08)   |
| IIB-IIA              | 2.28 (1.05 to 4.91) | 0.85 (0.30 to 2.40)   |
| IIIB-IVA             | 1.03 (0.56 to 1.89) | 0.38 (0.16 to 0.90)   |
| Time to FSA          |                   |                       |
| ≤ 30 days            | 1                  | 1                     |
| > 30 days            | 8.52 (3.34 to 21.76) | 11.52 (4.32 to 30.66) |
| Treatment protocol   |                   |                       |
| Surgery†             | 1                  | 1                     |
| Chemoradiation       | 1.84 (1.04 to 3.24) | 4.56 (1.81 to 11.47)  |
| Treatment adequacy   |                   |                       |
| Inadequate           | 1                  | 1                     |
| Adequate             | 1.64 (0.95 to 2.85) | 2.57 (1.26 to 5.40)   |

Abbreviations: FSA, first specialist assessment; OR, odds ratio.
*Adjusted by education and all other variables in the model.
†Surgery only or surgery combined with radiation and/or chemotherapy.

developed countries have issued recommendations for good practice establishing that waiting times for radiotherapy initiation should not exceed 14 days, with a maximum acceptable delay of 28 days.42-44 In our sample, the median time from diagnosis to treatment initiation presented no significant variation according to the type of first treatment (surgery or radiation), whereas the prevalence of treatment delay was greater than 80% in the surgery/radiation group. The multiple analyses showed that the chemoradiation protocol group had a chance of treatment delay 4.56 times higher than those treated with surgery/radiation plus radiation. Although such findings may still be affected by a residual confounding effect of the timing from diagnosis to FSA, the 60-day acceptable waiting time from diagnosis to treatment initiation was not achieved for the majority of our studied population. According to the regular cervical cancer care pathway (Fig 2), after the FSA, the time to treatment initiation depends on staging, treatment protocol definition, and preradiotherapy referral, which includes appraisal and prechemoradiation tests.

Treatment adequacy was highly associated with treatment delay, which is also related to stage and treatment protocol. Thus, women with adequate treatment were more likely to delay treatment initiation if they presented with late-stage disease (IIIB to IVA) at diagnosis (Table 3). Nevertheless, in the multivariable analysis, patients in the late stages were less likely to delay treatment. Such findings could be explained by the fact that women with late stages usually display symptoms such as pain, followed by bleeding, constipation, and so on.33 Therefore, in a scenario of an opportunistic screening program, such patients are more likely to be diagnosed and seek a specialized center for treatment. Once they have their FSA, they are usually prioritized for treatment initiation, because several studies have shown that for every day of extension in overall treatment time, there is a loss of approximately 1% of local tumor control, particularly in patients with cervical cancer at stages III to IV.45,46 However, because such patients often present with a poorer overall clinical condition, they are more likely to have unscheduled interruptions during radiotherapy, either prolonging the overall treatment time or interrupting the treatment because of toxicity, leading to a shorter interval from diagnosis to treatment completion.15 Therefore, women with cervical cancer presenting at stages IIIB to IVA would frequently show more symptoms and poorer health conditions, leading doctors to prescribe a treatment protocol other than the one officially recommended for such stages to adjust to the patient’s ability to bear the treatment’s toxicity and adverse effects. However, the effect of adequate protocol combined with delay in treatment initiation on cervical cancer survival, according to stage at diagnosis, still must be investigated.

To our knowledge, this study was the first to evaluate delays in treatment initiation in a cohort of Brazilian women with cervical cancer, cross-tabling the HCR database with medical reports and histopathologic results. Also, this study has the largest sample size in the same cancer center in Brazil, allowing the evaluation of a group of patients receiving the same standard treatment protocol. This fact provides an opportunity to translate the findings directly into practice, because surveillance regarding the waiting time for treatment initiation could be implemented in a health care center. However, considering that this is a retrospective study, a few limitations must be addressed. First, we could not evaluate most patient factors that prevent health care–seeking and compliance. These factors include confusion or limited knowledge regarding the process of seeking and using preventive and specialized care services. They also include denial or fear, the precedence of competing obligations (transportation, financial, childcare, work labor, and so on) as a rationale for nonadherence to scheduled visits and test taking, embarrassment, and signs and symptoms before diagnosis. Second, although we were able to estimate the delays in cervical cancer treatment initiation at NCI in Brazil, the lack of information on medical reports about the reasons either the surgery was canceled or the radiation was scheduled for more than 2 weeks after treatment definition, as well as potential confounders such as screening history of cervical cancer, limited the analyses.

Increased treatment initiation delay (greater than 90%) was observed in a public specialized cancer center in Brazil, and the timing from diagnosis to the FSA was the main factor independently associated with such a delay. Age, chemoradiation, and adequate treatment were positively associated with treatment initiation delay, whereas stage at
diagnosis was inversely associated. Prospective studies identifying the competing factors related to patients and potential treatment initiation delays should be conducted in the future. Furthermore, the effect of treatment initiation delays on survival must also be investigated in the future.

AFFILIATIONS
1^Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
2^Brazilian National Cancer Institute, Rio de Janeiro, Brazil
3^Fernandes Figueira Institute – Fiocruz, Rio de Janeiro, Brazil

CORRESPONDING AUTHOR
Ileia Ferreira da Silva, MSc, Av Rui Barbosa, #716, Flamengo, Rio de Janeiro, 22250-020 – RJ, Brazil; e-mail: ilce.silva@iff.fiocruz.br.

REFERENCES
1. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11 [internet]. International Agency for Research on Cancer, Lyon. https://www.researchgate.net/publication/304460791_GLOBOCAN_2012_v10_cancer_incidence_and_mortality_worldwide_IARC_cancer_base_no_11_International_Agency_for_Research_on_Cancer_Lyon
2. Jung HM, Lee JS, Lainson DR, et al: The effect of national cancer screening on disparity reduction in cancer stage at diagnosis by income level. PLoS One 10:e0136036, 2015
3. Azevedo e Silva G, Garianelli VR, Gamarra CJ, et al: Cervical cancer mortality trends in Brazil, 1981-2006. Cad Saude Publica 26:2399-2407, 2010
4. de Almeida FM, de Oliveira JC, Martins E, et al: Monitoring the profile of cervical cancer in a developing city. BMC Public Health 13:563, 2013
5. Costa RFA, Longatto-Filho A, Pinheiro C, et al: Historical analysis of the Brazilian cervical cancer screening program from 2006 to 2013: A time for reflection. PLoS One 10:e0138945, 2015
6. Barbosa IR, Souza DLB, Bernal MM, et al: Desigualdades regionais na mortalidade por câncer de colo de útero no Brasil: Tendências e projeções até o ano 2030 [in Portuguese]. Cien Saude Colet 21:253-262, 2016
7. Sousa AM, Teixeira CCA, Medeiros SD, et al: Mortalidade por câncer do colo do útero no estado do Rio Grande do Norte, no período de 1996 a 2010: tendência temporal e projeções até 2030 [in Portuguese]. Epidemol Serv Saude 25:311-322, 2016
8. Vale DB, Sauvaget C, Muwonge R, et al: Disparities in time trends of cervical cancer mortality rates in Brazil. Cancer Causes Control 27:889-896, 2016
9. Chen SW, Liang JA, Yang SN, et al: The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. Radiother Oncol 67:69-76, 2003
10. Robinson KM, Christensen KB, Ottesen B, et al: Socio-demographic factors, comorbidity and diagnostic delay among women diagnosed with cervical, endometrial or ovarian cancer. Eur J Cancer Care (Engl) 20:653-661, 2011 DOI:10.1111/j.1365-2354.2011.01259.x
11. Bennah M, Obel M, Bendahhou K, et al: Sociodemographic factors and delay in the diagnosis of cervical cancer in Morocco. Pan Afr Med J 12:14, 2012
12. Perri T, Issaković G, Sten-Baruch G, et al: Effect of treatment delay on survival in patients with cervical cancer: A historical cohort study. Int J Gynecol Cancer 24:1326-1332, 2014
13. Janssen-Heijnen ML, Maas HA, Houterman S, et al: Comorbidity in older surgical cancer patients: Influence on patient care and outcome. Eur J Cancer 43:2179-2193, 2007
14. Mackillop WJ, Zhou Y, Quirt CF: A comparison of delays in the treatment of cancer with radiation in Canada and the United States. Int J Radiat Oncol Biol Phys 32:531-539, 1995
15. Coles CE, Burgess L, Tan LT: An audit of delays before and during radical radiotherapy for cervical cancer – effect on tumour cure probability. Clin Oncol 15:47-54, 2003 DOI:
16. Chafe S, Honore L, Pearcey R, et al: An analysis of the impact of pathology review in gynecologic cancer. Int J Radiat Oncol Biol Phys 48:1433-1438, 2000
17. Gyanwali D, Khanal G, Paudel R, et al: Estimates of delays in diagnosis of cervical cancer in Nepal. BMC Womens Health 14:29, 2014
18. Yun YH, Kim YA, Min YH, et al: The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. Ann Oncol 23:2731-2737, 2012

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wc or ascopubs.org/jgo/site/misc/authors.html. No potential conflicts of interest were reported.

ACKNOWLEDGMENT
The authors thank Nelson Szilard Galgoul for the English text review.
19. Fedewa SA, Edge SB, Stewart AK, et al: Race and ethnicity are associated with delays in breast cancer treatment (2003-2006). J Health Care Poor Underserved 22:128-141, 2011
20. Hansen RP, Vedsted P, Sokolowski I, et al: Time intervals from first symptom to treatment of cancer: A cohort study of 2,212 newly diagnosed cancer patients. BMC Health Serv Res 11:284, 2011
21. Walter F, Webster A, Scott S, et al: The Andersen Model of Total Patient Delay: A systematic review of its application in cancer diagnosis. J Health Serv Res Policy 17:110-118, 2012
22. Weller D, Vedsted P, Rubin G, et al: The Aarhus statement: Improving design and reporting of studies on early cancer diagnosis. Br J Cancer 106:1262-1267, 2012
23. Brookfield K, Cheung MC, Lucci J, et al: Disparities in survival among women with invasive cervical cancer. Cancer 115:166-178, 2009 DOI:
24. McLaughlin JM, Anderson RT, Ferketich AK, et al: Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 30:4493-4500, 2012
25. Cardoso F, Castiglione M: On behalf of the ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 (suppl 4):15-18, 2009
26. Elmore JG, Nakano CY, Linden HM, et al: Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. Med Care 43:141-148, 2005
27. Viswanathan AN, Thomasden B. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of cervix. Part I: General principles. Brachytherapy 11: 33-46, 2012
28. Koh W-J, Greer BE, Abu-Rustum NR: Cervical cancer, version 2.2015. J Natl Compr Canc Netw 13:395-404, 2015
29. Brasil. Ministério da Saúde. Vigilância em Saúde Suplementar: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico (recurso eletrônico) / Ministério da Saúde, Agência Nacional de Saúde Suplementar. – Brasília: Ministério da Saúde, 2018
30. Brasil, Ministério da Saúde, Secretaria de Assistência à Saúde. Portaria no 876, de 16 de março de 2013. Dispõe sobre a aplicação da Lei nº 12.732, de 22 de novembro de 2012, que versa a respeito do primeiro tratamento do paciente com neoplasia maligna comprovada, no âmbito do Sistema Único de Saúde (SUS). Diário Oficial da União (DOU), Brasília, 2013
31. Presidência da República: Casa Civil: Subchefia para Assuntos Jurídicos. http://www.planalto.gov.br/ccivil_03/_ato2011-2014/2012/lei/l12732.htm
32. Jusbrasil: Lei 5809/10 Lei no 5809, de 25 de agosto de 2010. https://gov-rj.jusbrasil.com.br/legislacao/1024923/lei-5809-10
33. Sobin LH, Gospodarowicz MK, Wittekind CH: TNM Classification of Malignant Tumors (ed 7). Hoboken, NJ, John Wiley & Sons, 2009
34. Benedet JH, Bender H, Jones H III, et al: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancer. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70:209-262, 2000
35. Peters WA III, Liu PY, Barrett RJ II, et al: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606-1613, 2000
36. Sedis A, Bundy BN, Rotman MZ, et al: A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 73:177-183, 1999 .
37. Capelle L, Stevens W, Brooks S: Management pathway for patients with cervical cancer in the Auckland region 2003-2007. J Med Imaging Radiat Oncol 55:337-343, 2011
38. Kim SP, Knight SJ, Tomori C, et al: Health literacy and shared decision making for prostate cancer patients with low socioeconomic status. Cancer Invest 19:684-691, 2001
39. Davis TC, Williams MV, Marin E, et al: Health literacy and cancer communication. CA Cancer J Clin 52:134-149, 2002
40. National Health Service: Ensuring better treatment: Going further on cancer waits. http://www.improvement.nhs.uk/Publications/tabid/56/Default.aspx
41. Joint Council for Clinical Oncology: Reducing Delays in Cancer Treatment: Some Targets. Royal College of Physicians, London, United Kingdom. 1993
42. Australian Council on Healthcare Standards: Australasian Clinical Indicator Report: 2001-2008 Determining the Potential to Improve Quality of Care. 10th Edition Australian Council on Healthcare Standards, 2008. http://www.achs.org.au/reports/
43. Wait time alliance report card. No time for complacency. Report card on wait times in Canada, 2010. http://www.waittimealliance.ca/media/2010reportcard/WTA2010-reportcard_e.pdf
44. Fyles A, Keane TJ, Barton M, et al: The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 25:273-279, 1992
45. Lanciano RM, Pajak TF, Martz K, et al: The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns-of-care study. Int J Radiat Oncol Biol Phys 25:391-397, 1993
46. Peters WA III, Liu PY, Barrett RJ II, et al: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant